Associated Genetic Biomarkers
NCI Definition: A WHO grade II tumor composed of a conspicuous mixture of two distinct neoplastic cell types morphologically resembling the tumor cells in oligodendroglioma and diffuse astrocytoma. (WHO) 
Oligoastrocytomas most frequently harbor alterations in IDH1, TP53, ATRX, TSC1, and TET2 .
IDH1 Mutation, IDH1 Codon 132 Missense, IDH1 R132H, TP53 Mutation, and TP53 c.217-c.1178 Missense are the most common alterations in oligoastrocytoma .
There are 3 clinical trials for oligoastrocytoma, of which 3 are open and 0 are completed or closed. Of the trials that contain oligoastrocytoma as an inclusion criterion, 1 is phase 1 (1 open) and 2 are phase 2 (2 open).
HLA-A*02, IDH1, and IDH2 are the most frequent gene inclusion criteria for oligoastrocytoma clinical trials .
Ima950, poly iclc, and proton beam radiation therapy are the most common interventions in oligoastrocytoma clinical trials.
Significant Genes in Oligoastrocytoma
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.